CTLA4 and type 1 diabetes mellitus: No significant difference was discovered in the incidence of T1DM in PAI patients on PD-1 inhibitors and the combination therapy of anti-PD-1 + anti-CTLA-4 (χ2 = 2.995, p = 0.084).